NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. EYPTF45 Training Holdings, Inc. FXLVPROG Holdings, Inc. PRGand Intuit, Inc. INTU. Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

EyePoint Pharmaceuticals, Inc. EYPT

On August 30, 2022, after the market close, EyePoint announced that it had received a subpoena from the United States Attorney for the District of Massachusetts. The subpoena requested documents covering the company’s sales practices for its post-surgical inflammation treatment DEXYCU.

As a result of this news, EyePoint stock fell $0.21 per share, or 2%, to close at $10.00 per share on August 31, 2022.

For more information on the EyePoint exam, visit: https://bespc.com/cases/EYPT

F45 Training Holdings, Inc. FXLV

On or about July 15, 2021, F45 Training completed its initial public offering (“IPO”), selling 18.75 million shares at a price of $16.00 per share.

Then, on July 26, 2022, F45 issued a press release titled “F45 Training Announces Strategic Update”. In the press release, F45 Training provided an updated 2022 revenue guidance in the range of $120-130 million, well below the previous guidance of $255-275 million, citing ongoing macroeconomic uncertainty. The press release also announced the departure of the company’s chief executive officer, Adam J. Gilchrist, and announced that the company was “reducing its global workforce by approximately 110 employees.”

As a result of this news, F45 Training’s stock price fell $2.16 per share, or 61.54%, to close at $1.35 per share on July 27, 2022.

For more information on the F45 investigation, visit: https://bespc.com/cases/FXLV

PROG Holdings, Inc. PRG

On 08/25/2022…